Forodesine

Forodesine

Names
IUPAC name 7-[(2S,3S,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one
Other names Immucillin H
Identifiers
CAS Number	209799-67-7 Y
3D model (Jmol)	Interactive image
ChemSpider	392417 N
KEGG	D06596 Y
PubChem CID	444499
UNII	426X066ELK N
InChI InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 N Key: IWKXDMQDITUYRK-KUBHLMPHSA-N N InChI=1/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 Key: IWKXDMQDITUYRK-KUBHLMPHBW
SMILES C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
Properties
Chemical formula	C11H14N4O4
Molar mass	266.26 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Forodesine (INN; also known as Immucillin H) is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).

Forodesine was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.

Forodesine is being developed by BioCryst Pharmaceuticals as Fodosine. As of 2008^[update], it is currently in phase II clinical trials..

In 2006, BioCryst announced an licensing agreement with Mundipharma International Holdings Limited (“Mundipharma”) to develop and commercialize Fodosine in markets across Europe, Asia, and Australasia for use in oncology.